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INTRODUCTION  
Gestational diabetes mellitus is one of the most challenging medical 
complications encountered during pregnancy. GDM is an iceberg disease. It is a 
common but a controversial disorder. The word gestational in GDM implies that 
diabetes is induced by pregnancy because of exaggerated physiological changes 
in glucose metabolism. WHO and the American diabetic association define 
GDM as any degree of glucose intolerance with onset or first recognition during 
pregnancy. GDM has gained at most importance nowadays because half of 
GDM women ultimately develop T II DM in the ensuing 20 years. Inutero 
exposure to hyperglycemia can lead to childhood diabetes. 
Prevalence of GDM ranges from 5 to 6%, which is affected by various 
factors like race, ethnicity, age, body composition, screening and diagnostic 
criteria. The fact that Asians are at high risk for development of GDM 
necessitates early diagnosis. Early diagnosis of GDM is very essential to initiate 
a comprehensive and multi disciplinary approach to prevent maternal and 
neonatal morbidity and mortality. There continuous to be several controversies 
regarding screening and treatment of GDM. Several screening tests have been 
introduced in the past 40 years. Early diagnosis of GDM using OGTT is done 
between 24 and 28 weeks of gestational age. But no tests are available before 
this gestational age, which can predict the development of GDM. In developing 
countries like ours, early detection and prevention of associated morbidity will 
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be more cost effective. Serum uric acid is associated with insulin resistance. 
Two mechanisms have been hypothesized by which uric acid can cause insulin 
resistance. Uric acid causes endothelial dysfunction and decreases nitric oxide 
production by endothelial cells. In animals insulin action on glucose uptake into 
cells in the skeletal muscles and adipose tissue is dependent on nitric oxide. 
Thus decrease in nitric oxide lead to decreased glucose uptake and the 
development of insulin resistance. Another mechanism is that uric acid may 
induce insulin resistance and causes inflammation and oxidative stress in 
adipocytes, which is a contributor to the development of metabolic syndrome. It 
has been proven that higher levels of uric acid are noted at 24 to 28 weeks of 
gestation in women with GDM when compared with women without GDM. 
Normally during pregnancy, the serum uric acid level decreases significantly 
between 8 and 24 weeks of gestation due to increased glomerular filtration rate 
and reduced re-absorption of uric acid from renal tubules. In first trimester, it 
likely approximates preconception uric acid level, and elevated levels may 
identify women who are predisposed to metabolic syndrome with an increased 
risk of developing gestational diabetes mellitus. This concept would be useful in 
predicting GDM at an earlier gestational age, there by aiding in initiating timely 
and appropriate management to prevent maternal and fetal morbidity and 
mortality. 
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AIM OF THE STUDY  
 
To correlate between first trimester uric acid level and its association with 
subsequent development of gestational diabetes mellitus 
  
4 
 
REVIEW OF LITERATURE  
 
Gestational diabetes mellitus is defined as carbohydrate intolerance of 
variable severity with onset or first recognized during pregnancy 
(ACOG,2013)1. 
Short history of gestational diabetes mellitus  
 The recorded history of diabetes in pregnancy over the past 200 years is 
essentially the story of recognition of the adverse effects of hyperglycemia on 
both mother and fetus. Much effort has been spent on the problem of 
categorizing the degree of hyperglycemia which would justify treatment and 
how to identify the mother at risk. 
 The first documented evidence of the effect of hyperglycemia in 
pregnancy in the modern era was in 1824, when Bennetwitz et al recorded a 
case of severe fetal macrosomia and stillbirth in 22 year old multi gravid 
women in Berlin2.    
However until the discovery of insulin in 1923 there was no effective 
treatment for this condition, and the outcome of pregnancy for both mother and 
the fetus was usually disastrous. Belgium researcher J.P.Hoet(1954) was the 
first to use the term “meta gestational diabetes” and published his study on 
“carbohydrate metabolism during pregnancy”3.  
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In 1967 Jorgen Pederson et al probably were the first to use the modern 
term “Gestational diabetes mellitus”4 and this was promoted by Frienkel.N et al 
in 1980 in Chicago who published a paper of  “Pregnancy and progeny”, 
incorporating several important insights on to the pathophysiology of glucose 
metabolism in both mother and the fetus5. 
The first international workshop conference on gestational diabetes 
mellitus in 19796, essentially declared, GDM as a disease with significant health 
risk that needed treatment. Thus instead of more neutral “carbohydrate 
intolerance of pregnancy” the term “Gestational Diabetes Mellitus” evolved.  
The first major prospective study was established in 1954 in Boston and 
the one hour 50 gm glucose screening test was used there. The result from this 
study presented by O Sullivan and Mahan et al in 1964 showed that 
hyperglycemia in pregnancy correlated with development of diabetes latter in 
life7. 
 
Prevalence of gestational diabetes mellitus 
 Globally, the prevalence ranges between 1 and 14% of all pregnancies 
(Person B et al)8. But studies conducted in different parts of country averages 
the incidence of GDM in Indian population to be 16.55% (Seshiah V et al 
2004).9 
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 The Australian carbohydrate intolerant study (ACHOIS) undertaken in 14 
centers in Australia and four centers in UK reported GDM affected 2 to 9 % of 
pregnancy (Crowther CA et al 2005)10.  
 Tuffnell, Whilst et al 2003 in their systematic review of treatment for 
GDM and impaired glucose tolerance (IGT), for seven cochrane data based 
study state that 3 to 6% pregnancies are affected by GDM11. 
Classification during pregnancy :(Williams Obstetrics book 24th  edition)50 
1. Etiological classification of diabetes mellitus: 50 
    Type 1: 
    β- cell destruction, usually absolute insulin deficiency 
    Immune- mediated 
     Idiopathic 
    Type 2: 
     Ranges from predominantly insulin resistance to predominantly an insulin 
secretary defect with insulin resistance 
     Other types: 
 Genetic mutations of beta cell function- MODY1-6,others  
 Genetic defects in insulin action 
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 Genetic syndromes-Down,Klinefelter,Turner 
 Diseases of the exocrine pancrease-pancreatitis,cystic fibrosis 
 Endocrinopathies-Cushing syndrome,pheocromocytoma,others 
 Drug or chemical induced-glucocorticoids,thiazides,β-adrenergic 
agonists,others 
 Infections-congenital rubella,cytomegalovirus,coxsackie virus 
 Gestational diabetes 
White classification in pregnancy (American journal of med 1949)79 
A: Abnormal glucose tolerance test at any age or of any duration treated only by 
diet therapy 
B: Onset at age 20 years or older and duration of less than 10 years 
C: Onset at age 10 to 19 years or duration of 10 to 19 years 
D: Onset before 10 years of age, duration over 20 years, benign retinopathy, or 
hypertension (not preeclampsia) 
– D1: Onset before age 10 years 
– D2: Duration over 20 years 
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– D3: Calcification of vessels of the leg (macrovascular disease) 
– D4: Benign retinopathy (microvascular disease) 
– D4: Hypertension (not preeclampsia) 
R: Proliferative retinopathy or vitreous hemorrhage 
F: Renal nephropathy with over 500 mg/d proteinuria 
RF: Criteria for both classes R and F 
G: Many pregnancy failures 
H: Evidence of arteriosclerotic heart disease 
T: Prior renal transplant 
Gestational diabetes 
– A1: Controlled by diet and exercise 
– A2: Requires insulin 
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Classification scheme recommended by ACOG (1986)50 
 
 
 
Now the ACOG (2012, 2013), no longer recommended the white classification. 
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Classification proposed by American Diabetes Association (2012)50 
Gestational diabetes: diabetes diagnosed during pregnancy that is not clearly 
overt (type 1or type 2) diabetes 
Type I Diabetes 
Diabetes resulting from β cell destruction leading to absolute insulin deficiency 
a. without vascular  complications 
b. with vascular complications 
Type II Diabetes 
Diabetes from inadequate insulin secretion in the face of increased insulin 
resistance 
a. with vascular complications 
b. without vascular complications 
Other types of Diabetes 
a. Genetic in origin 
b. Associated with pancreatic disease 
c. Drug induced 
d. Chemically induced 
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Pathogenesis  
 Pregnancy is a condition of  
1. Accelerated starvation 
2. Facilitated anabolism 
3. Hyperinsulinism  
4. Insulin resistance  
 
 
          Increased placental lactogen, progesterone,and cortisol during pregnancy 
results in increased insulin resistance and development of GDM. 
Pregnancy confers a state of insulin resistance and hyperglycemia that 
predisposes women to develop diabetes. GDM occurs when women pancreatic 
function is not sufficient to overcome the diabetogenic environment of 
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pregnancy. Basal glucose and insulin level remains unchanged in early trimester 
and glucose is normal (Butte NF et al 2000)12. 
As pregnancy progresses, basal as well as postprandial insulin secretion 
increases to reach twice the non-pregnant value by the 3rd trimester(Lesser KB 
et al 1994)13. 
Insulin sensitivity in late normal pregnancy is 45 to 70% lower than that 
of non-pregnant women (Freemark et al 2006)14. 
 
Mechanism responsible for insulin resistance 
 Plasma levels of placental lactogen increases with gestation. Higher 
levels may increases lipolysis and liberation of free fatty acids (Frienkel, 1980)5 
This increased free fatty acid concentration may aid increased tissue 
resistance to insulin. 
 When insulin levels and responses are expressed relative to each 
individual’s degree of insulin resistance, a large defect in pancreatic β cell 
function is consistently found in women with prior GDM( Bachanan et al 
2001)15 
 Defects in the binding of insulin to its receptor in skeletal muscle do not 
appear to be involved in insulin resistance in GDM (Damm P et al 1993)16. 
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Other defects, like alteration in insulin signaling pathway, reduced expression of 
PPARγ and reduced insulin mediator glucose transport have been found in 
skeletal muscle or fat cells of women with GDM(Xiang AH et al 2005) 17. 
  Recently development of GDM is triggered by an antigenic load which is 
the fetus itself. Human leukocyte antigen – G (HLA – G) expression which 
functions to protect the fetus from immune attack by down regulation cytotoxic 
T cell responses to fetal trophoplast antigen is postulated to protect pancreas as 
well. The interaction between HLA- G and nuclear factor – KB (NF- KB) is the 
central event leading to GDM development. In future it may be possible to use 
recombinant HLA gene for prevention of GDM in high risk patients (Oztekin- 
O, 2007).18 
 
Problems due to gestational diabetes mellitus  
 Both overt diabetes mellitus and gestational diabetes mellitus pose many 
risks to the mother as well as fetus.  
MATERNAL: 
 Increased risk of preeclampsia 
 Increased risk of caesarean section 
 Polyhydramnios 
 Preterm labour 
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 Post partum haemorrhage 
 Nephropathy 
 Retinopathy 
 Increased incidence of infection/hypo and hyperglycaemia, DKA 
 Later –recurrent GDM 
          -TII Diabetes mellitus 
FOETAL: 
 Macrosomia 
 Congenital malformation 
 Neonatal hypoglycemia 
 Hyperbilirubinemia 
 Hypocalcaemia 
 Birth trauma 
 Early childhood obesity  
 
Maternal effects 
 Gestational diabetes mellitus have increased risk of pre eclampsia. It 
occurs in 10 % of women with GDM. Gaggar F et al 2005 found that most 
common complication in GDM patients are gestational hypertension(36.4%) 
followed by abruption placenta(20%)19 
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 Many studies have shown pre eclampsia develops in younger nulliparous 
, obese and in women who gains significant weight in pregnancy. Risk of super 
added preeclampsia is 35 to 60% in women who have micro albuminuria in 
early pregnancy. Pre eclampsia occurs in women with pre gestational diabetes is 
well documented but there are conflicting reports as to the effect of GDM on 
development of hypertensive disorders (Joffe GM et al 1998).20 
 There was 10 % increased risk of polyhydromnios in women with GDM. 
Dashe and colleagues in 2000 found that amniotic fluid index parallels the 
amniotic fluid glucose level among women with diabetes 21. In 2006 Vink and 
associates linked poor maternal glucose control to macrosomia and 
hydromnios.22 Women with elevated glycosylated hemoglobin (HbA1c) value in 
3rd trimester were more likely to have hydromnios (Idris et al 2010)23.  
  Risk of preterm labor chorio amnionitis and urinary tract infection also 
increased. Women with GDM developed twice the number of urinary tract 
infection than who don’t have GDM due to increased glucose in urine beyond 
normal glycosuria in pregnancy (Ian Donald’s practical obstetric problems) 24 
  Certain tocolytics and antenatal steroid given in pregnancy complicated 
by preterm labor worsen the hypoglycemia and predispose the women to 
ketoacidosis. Fever and dehydration also precipitates ketoacidosis and sudden 
fetal loss. 4 to 15% of maternal mortality occurs due to keto-acidosis in 
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pregnancy. It is increasingly reported in women with type 2 or even those with 
gestational diabetes mellitus (Sibai, 2014).25 
 The risk of developing type 2 diabetes mellitus after pregnancy in women 
with gestational diabetes is 10% per year. The incidence is high in first five 
years after pregnancy and then decreases (Neston et al 2002).26 
 Similar to women with overt diabetes, GDM is also associated with 
increased frequency of caesarian section rate. Gagger et al 2005 found that 
19.15% increased caesarian rate in women with gestational diabetes mellitus 19. 
After delivery women with GDM have increased risk for metabolic syndrome, 
disturbed endothelial function and are prone to develop cardiovascular 
morbidity ( Valpreda S et al 2007)27 
Effects of GDM on the fetus (Arias’ High risk pregnancy and delivery book 
4th edition) 36 
 Fetal effects include  
1. Abnormalities in growth – macrosomia, growth restriction and 
congenital malformation 
2. Fetal oxygenation problem – Sudden intrauterine death, 
respiratory distress syndrome 
3. Chemical imbalance after delivery 
4. Long term sequlae 
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1. Abnormalities in growth 
Maternal hyperglycemia leads to fetal hyperinsulinemia which is 
responsible for increased fat deposition and macrosomia, organomegaly, 
increased erythropoietin and reduced surfactant production (Pederson J et al)4. 
Some authors also suggest that maternal obesity rather than GDM may be the 
determining factors in development of macrosomia (Oken N et al 1997, Dang 
K et al 2000)28  
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Macrosomia leads to increased risk of shoulder dystocia. There was three 
fold increased risk of shoulder dystocia when birth weight is more than four 
thousand gram ( Acker DB 1985;Ginsberg NA et al 2001)29. It also increases 
the risk of intra partum asphyxia, respiratory distress syndrome and 
polycythemia. ACOG suggest that if GDM remains undiagnosed or untreated 
the risk of macrosomia is high as 20 %( Chatfield J, 2001)30 
The HAPO study 200831 showed a strong correlation between maternal 
glucose levels (even below the values diagnosis of GDM) and increased in birth 
weight and cord blood serum C peptide levels. Unlike overt diabetes, rates of 
congenital anomalies don’t appears to be increased in women with GDM 
(Sheffield  JS 2002)32. Maternal glycosilated hemoglobin level in first trimester 
helps to predict it. 
 
2. Fetal oxygenation problems 
 Oxygen consumption increased by 30% in gestational diabetes. Increased 
erythropoietin secretion results in polycythemia and hyperviscosity which 
causes neonatal strokes, seizures, neonatal enterocolitis and sudden fetal 
demise.(IAN DONALD’S practical obstetrics book) 24 
 
19 
 
Sudden fetal death occurs due to 
1. Maternal hypoglycemia 
2. Ketoacidosis  
3. Chronic hypoxia  
4. Placental villous edema impairs nutrient transfer 
           In 2003, American diabetic association concluded that fasting blood 
sugar more than 105mg/dl is associated with increased risk of fetal death during 
the final 4 to 8 weeks33. 
3. Chemical imbalance 
 Maternal hypoglycemia causes fetal hypoglycemia results in sudden 
intrauterine death.   Other complications like hypocalcaemia and 
hypomagnesaemia within 72 hours of birth. Risk of hyperbilirubinaemia is 
increased due to preterm delivery and ineffective erythropoiesis. Incidence of 
hypoglycemia and hyperbilirubinemia increased in gestational diabetes. Iron 
deficiency anemia also occurs, which results in neuro developmental and 
behavioural abnormalities (Lozoff B et al 2000)34 
4. Long term complications 
 Infants of gestational diabetes mellitus have increased risk of developing 
obesity, type 2 diabetes, cognitive impairment and cardiovascular diseases(Tam 
WH, Yang X et al 2008)35 
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Risk assessment and various screening test for gestational diabetes mellitus 
(ARIAS” HIGH RISK PREGNANCY AND DELIVERY 4th EDITION)36 
Low risk (Blood sugar screening not routinely required) 
1. Members of ethnic group with low prevalence of GDM 
2. Age less than 25 years 
3. No known diabetes in first degree relatives 
4. No history of abnormal glucose metabolism 
5. Normal weight before pregnancy 
6. Normal weight at birth 
Moderate risk (these women needs blood sugar testing at 24 to 28 weeks- 1 or 
2 step procedure) 
1. Members of ethnic group with high prevalence of GDM 
2. Age more than 25 years 
3. Diabetes in first degree relatives 
4. Over weight before pregnancy 
5. Weight high at birth 
High risk (In these women blood sugar testing should be done as soon as 
possible) 
1. Marked obesity 
2. Strong family history of type 2 diabetes 
3. Previous history of GDM, impaired glucose metabolism or glycosuria 
4. High risk ethnic group( Indian, African, Hispanic and middle eastern) 
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Screening tests 
 There is a debate regarding the preferred screening protocol for 
gestational diabetes mellitus. First screening test for GDM was proposed in 
1973.When universal screening is employed, patient with no risk factor should 
undergo one hour glucose test (GCT) at 24 to 28 weeks of gestation. Patient 
with known risk factors that indicate the possibility of glucose intolerance may 
be tested at the onset of prenatal care. 
Two step tests:- 
 According to 1997 recommendations by American Diabetes 
Association’s Fourth International Workshop on GDM 37 screening and 
diagnosis were undertaken as a two step approach. Initially screening is done 
with 50 gm of glucose challenge test. Patient receives 50 grams of glucose and 
one hour later, blood is drawn for testing. A glucose value above 140 mg/dl is 
considered as abnormal and then patients are subjected to the second test, three 
hour glucose tolerance test with 100 grams of glucose. 
Diagnosis of GDM by 100gm 3-hr OGTT by Carpenter and Coustan 
(1982)38 
  To perform glucose tolerance testing (OGTT), clinician first draws a 
fasting glucose sample and administered100 gram of glucose. Blood for glucose 
value is drawn at 1 hour, 2 hour and 3 hours. 
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Carpenter coustan 
criteria(1982) 
National diabetes data 
group 
FBS 95mg/dl 105mg/dl 
1 hour 180mg/dl 190mg/dl 
2 hour 155mg/dl 165mg/dl 
3 hour 140mg/dl 145mg/dl 
 
Two or more values should be abnormal for diagnosis. 
 ACOG 2001 practice bulletin states that universal screening is the most 
sensitive and more practical approach but it notes that low risk women may be 
excluded from screening as per the American diabetic association (ADA) 
recommendation. (ACOG practice bulletin September 2001)39 
 “NICE guidelines 200840” recommended screening at 24 to 28 weeks 
using 75 gram OGTT. Diagnosis made on basis of criteria defined by WHO 
(FBS ≥ 126 mg/dl and 2 hour value of 140 mg/dl) 
ACOG 2013 recommended two step tests41. 
Single step approach:- 
1. Diabetes in pregnancy study group (DIPSI) 42 recommended a single step 
diagnostic procedure for all patients (Universal screening). This has been 
approved by Ministry Of Health, Govt. Of India and also by WHO. 
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Procedure:- 
 Pregnant women is given 75 grams glucose orally irrespective of 
her fasting status or timing of last meal. GDM is diagnosed if the post 
prandial 2 hour value is more than 140 mg/dl. 
2. HAPO trial 200831 
The study was conducted in 25000 Caucasians using 75 gram oral 
glucose tolerance test between 24 and 32 weeks gestation(Metzegerbe et 
al 2010).The values are analyzed with birth weight >90th percentile, 
neonatal hypoglycemia, primary caesarean section rate, cord –serum c-
peptide level >90th percentile. 
HbA1c or FBS or RBS (1st antenatal visit) 
 
A1c >6.5% or  A1c 5.7 to6.4% or    A1c < 5.7% or 
FBS>126mg/dl or  FBS >92mg/dl but    FBS < 92mg/dl 
RBS >200mg/dl  ≤ 126mg/dl 
            
            
   
Overt diabetes          GDM    OGTT at 24 to 28 
weeks            
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If abnormal - GDM  
American diabetic association(2013) and International association of 
diabetes and pregnancy study(IADPSG) in 2010 recommended one step test 
using 75 gram 2 hour OGTT based on HAPO trial( Hyperglycemia and 
pregnancy outcome) 
75 gram 2 hour OGTT test (IADPSG guidelines 2011)43 
Preparation of patient:- 
• Unrestricted diet in previous 3 days 
• Overnight fasting 8 to 14 hours 
• Test done in morning 
• Should not be ambulated 
• Smoking avoided 
Criteria to diagnose:- 
• Fasting >92 mg/dl(5.1mmol/L) 
• 1 hour >180mg/dl(10.0mmol/L) 
• 2 hour >153 mg/dl (8.5mmol/L) 
Diagnosis is made when any one value is exceeded. 
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Cut off values are lower than traditional value and were considered after result 
of HAPO trial, suggested increased complications even below the cut offs in 
traditional tests. 
 Traditional test (Carpenter and NDDG guidelines) cut offs were based on 
data that was derived mathematically, but in recent guidelines (ADA and 
IADPSG) cut offs were derived from adverse outcomes at mean glucose level of 
HAPO study. 
         Maternal glycosylated hemoglobin levels in first trimester helps to predict 
the occurrence of congenital anomalies in pregestational diabetes (Kicklighter 
SD .2001)44 
          HBA1C <7%-No greater risk 
          7.8 -9.5% - 5 % Anomalies 
          >10 % -22 %Anomalies 
          So HbA1C up to 6.5 % was considered normal and acceptable for the first 
trimester control 
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Various screening test criteria’s for GDM diagnosis (Management of high 
risk pregnancy book 2nd edition) 80 
 Method Screen positive Diagnostic test Threshold level 
WHO One step NA 75gm OGTT Fasting>126mg/dl 
2hours≥140mg/dl 
One annormal 
value needed for 
diagnosis 
DIPSI One step NA 75gm 
OGTT(irrespective 
of fasting status) 
2 hours≥140mg/dl 
ACOG Two step 50gm GCT 
glucose≥135mg/dl 
or≥140mg/dl is 
elevated.the lower 
threshold should 
be consideredin 
population with 
higher prevalence 
of GDM 
100gm OGTT Fasting≥95mg/dl 
1hour≥180mg/dl 
2hour≥155mg/dl 
3hours≥140mg/dl 
More than 2 
abnormal value 
needed for 
diagnosis 
ADA One step NA 75gm OGTT Fasting≥92mg/dl 
1hour≥180mg/dl 
2hour≥155mg/dl 
One abnormal 
value needed for 
diagnosis 
IADPSG One step NA 75gm OGTT Fasting≥92mg/dl 
1hour≥180mg/dl 
2hour≥153mg/dl 
One abnormal 
value needed for 
diagnosis 
CDA Two 
step(preferred) 
Or one step 
50gm GCT(2step) 
glucose≥140mg/dl 
75gm 
OGTT(1STEP) 
Fasting 
1hour 
2hour 
One abnormal 
value needed for 
diagnosis 
 
• DIPSI-Diabetes in pregnancy study group India 
• WHO-World health organization 
• ACOG-American college of obstetrics and gynaecology 
• ADA-American diabetes association 
• CDA-Canadian diabetic association 
• NA-Not applicable 
• IADPSG-International association of diabetes and pregnancy study group 
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Uric acid 
          Uric acid is the end product of purine degradation45.They is derived from 
both from breakdown of body proteins and also from diet. The richest sources 
of purines includes kidney, liver, sardine, lentils, sweet bread, anchovies, 
mushrooms, asparagus and spinach. Uric acid is excreted thro kidneys. 2/3rd of 
uric acid is excreted via the kidneys and the remaining is excreted via the stool. 
The level of uric acid that will cause GDM is not known. It has been recognized 
in recent years that the normal ranges of uric acid is varying widely.  Serum uric 
acid levels has to be tested several times over a period as it has a wide normal 
range as well as the uric acid level varies day  to day and shows seasonal 
variation in the same person. Urine uric acid level also used to diagnose gout.  
Serum uric acid reference value (Lippincott Williams book 9th edition 2011)46 
• Adult male – 2.5 to 8mg/dl 
• Adult female- 1.9 to 7.5mg/dl 
Uric acid level fall by1/3rd in early pregnancy and reaches non-pregnant level by 
term. 
• Children ages 10 to 18 years 
Males - 3.6 to 5.5mg/dl 
Females - 3.6 to 4.4mg/dl 
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• Elderly  
Male – 2 to 8.5mg/dl 
Female – 2 to 8 mg/dl 
Normal range of urinary uric acid is 250 to 750mg/24 hours. It is important to 
check laboratory reference values for each setting.  
Conditions associated with hyperuricemia:-(Mark D et al, 1999)47 
1. Renal failure 
2. Alcoholism 
3. Gout  
4. Dehydration  
5. Leukemia and lymphoma 
6. Starvation  
7. Metabolic acidosis  
8. Toxemia of pregnancy 
9. Infectious mononeucleosis  
10. Hyperlipidemia  
11. Hemolytic anaemia  
12. Chemotherapy and radiotherapy 
 
29 
 
Changes is uric acid concentrations during normal pregnancy (Lind T et al 
,1984)48 
 Serum uric acid concentrations have been studied in a group of healthy 
women before conception, at regular intervals throughout pregnancy and 12 
weeks after delivery. Serum uric acid level is decreased at 8 weeks of pregnancy 
when compared to the pre pregnancy levels and this decreased level was 
maintained upto24 weeks of pregnancy. Then there will be a raise in the uric 
acid concentration to reach a level above the pre-pregnancy value and remains 
elevated for a period of 12 weeks in the post partum period. If clinical 
management during the second half of pregnancy is to be based on increase in 
serum uric acid concentration, then such increase will have to be carefully 
interpreted against the raise in concentration which occurs as part of 
physiological response to normal pregnancy.   
 In the year 1989 Carter J et al49 published that the fall in the early 
trimester is due to the effect of estrogen and increased plasma volume and 
glomerular filtration rate 
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Changes in normal pregnancy (Williams Obstetrics 24th Edition) 50  
  
Normal values(mg/dl) 
Pre-pregnancy 2.5 to 5.6 
First trimester 2.0 to 4.2 
Second trimester 2.4 to 4.9 
Third trimester 3.1 to 6.3 
 
Uric acid is also associated with insulin resistance in non- pregnant individuals 
(Halkin H et al,(1987)51 
Association between uric acid and GDM 
 The association between uric acid and insulin resistance is causal. Two 
mechanisms have been hypothesized by which uric acid causes insulin 
resistance. In the year 2003, Cook S et al studied in animals that insulin action 
on glucose uptake into the cells in the skeletal muscles and the adipose tissues 
which depends on nitric oxide and this reduced nitric oxide leads to reduced 
glucose uptake and development of insulin resistance52.  
 Nakagawa et al,(2005) states that uric acid causes endothelial dysfunction 
and decreased nitric oxide production by the endothelial cells53. Another 
mechanism is that uric acid causes inflammation and oxidative stress in adipose 
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tissues which is associated with onset of metabolic syndrome in mice 
(Farukawa – S et al 2004: Sautin- YY et all 2007) 54 . 
 
    Hyper uricemia during the first trimester of pregnancy is associated with high 
risk of developing GDM. There was 3.25 fold higher risk of developing GDM 
when the uric acid level in first trimester was in the 4th quartile(S Katherine 
Laughon et al, (2009)55. 
     Even though the uric acid was strongly associated with BMI, the risk of 
developing GDM was increased among women with elevated uric acid level in 
first trimester of pregnancy which is independent of BMI55. 
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                       In2009 Laughon et al ,(2009)55;showed that , Serum uric acid 
level during the first trimester of pregnancy likely approximates pre-conception 
level of serum uric acid, and raised level of uric acid may identify women who 
are at the risk of developing metabolic syndrome with an increased risk of 
developing GDM, independent of obesity. Alternatively, uric acid decreases 
early in pregnancy, so perhaps women with elevated uric acid have a poor 
adaptation to pregnancy (i.e. abnormal placentation), putting them at risk for 
adverse pregnancy outcomes such as GDM.  
 
Association between uric acid and GDM 
 Simmi kharb et al (2000)56 studied the relationship between ascorbic acid 
and uric acid levels in women with gestational diabetes mellitus. He stated that 
significant low vitamin c levels and high serum uric acid levels were observed 
in women with GDM in their study. 
 In 2006 Gungor ES, Danishman N et al (2006)57 conducted a study 
regarding association between serum uric acid, creatinine, albumin  and 
development of GDM. 
 Laughon et al in 200955 concluded serum uric acid in the highest quartile 
had 3.25 fold increased risk of developing GDM. This effect was concentration 
dependent.  
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 Rasika C et al in their study from 201458 concluded that the first trimester 
elevated uric acid concentration is associated with increased risk of GDM 
development. 
 Jianjun zhou, xiazhao et al(2012)59 measured lipids and uric acid 
concentration at 20 weeks of gestation and showed hyperurecemia have 
increased risk of development of pre-eclampsia and GDM.  
            In 2012, wolak t et al conducted a study and concluded elevated uric 
acid in first 20wks of pregnancy is associated with higher risk for GDM and 
preeclampsia.60 
           Sindhiya anbalagan, mirunalinie et al 2012-201461 conducted a study and 
concluded rise in serum uric acid showed statistical significance in development 
of GDM. 
           In 2013 Aparna Kappaganthu ,sachan et al studied that increased uric 
acid in first trimester have associated with onset of GDM62. 
          Shery Angel Rajkumar et al,(2014)63 concluded that patients with 
abnormal uric acid level in first trimester had higher risk of developing GDM. 
          In the year 2015, Balinga Pundalik and Thanga suchitra et al64, studied 
175 pregnant women out of which 8 developed GDM and concluded uric acid 
in early pregnancy as a predictor of GDM 
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Possible effects of early diagnosis of GDM  
1. Reduction in perinatal mortality rate 
       Increased fetal death occurs due to undiagnosed GDM. The overall 
decrease in perinatal mortality in recent years due to better antenatal 
surveillance and earlier intervention (Morb Mortal Wkly 2002)65 
         In 2004, Benerjee et al, found that early diagnosis and effective management 
resulted in 60% reduction in perinatal mortality66 
2. Reduction of rate of Macrosomia: 
     Langer et al, 199467 showed a significantly reduced incidence of both 
macrosomia and shoulder dystocia using an intensified management strategy.  
    There are fairly consistent data showing that screening and subsequent 
management of GDM may reduce the incidence of macrosomia.(Naylor et al 
1995)68. 
3. Reduction in preeclampsia: 
     There are conflicting reports as to the effect of GDM on development of 
hypertensive disorders of pregnancy (Joffe GM et al, 1998).Alwan et al., 2009 
in their study concluded that effective surveillance and treatment of GDM has 
positive benefit on preeclampsia occurrence.69 
4. Reduction in caesarian section rate: 
     Tuffnell; Alwan N et al.,(2009)69 showed 54% reduction in caesarian section 
rate in their study due to better surveillance and early intervention. 
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5. Reduction of immediate neonatal metabolic complications related to 
maternal hyperglycemia 
       Many neonatal units have surveillance protocol for both babies of GDM 
mothers and macrosomic babies without a maternal history of GDM. 
        Curet LB et al.,in 1997 and Naeham Z et al., in (1999 )showed that 
maternal euglycaemia , hypocalcaemia, hyperbilirubinemia ,and polycythemia70 
6. Prevention of long term effects of GDM  on both the mother and the 
child: 
         Wein P et al in 1993 had stated that earlier identification of GDM had 
some health benefits due to consequent increased surveillance and early 
diagnosis of TII diabetes mellitus.71 
         In 1998, vohr BR et al., had reported a significant reduction in the 
incidence of Diabetes and obesity in childhood of GDM mothers with early 
diagnosis and effective management.72  
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MATERIALS AND METHODS  
 
This is a prospective study conducted at Govt. Raja Mirasudar Hospital 
attached to Thanjavur Medical College, Thanjavur. The study was conducted 
over a period of one year from September 2015. The sample size was 
ascertained after a power calculation with the help of statistician. A total of one 
hundred and eighty seven ante natal women less than 14 weeks of gestational 
age who attended the outpatient antenatal department were included in this 
study. Aim of study was explained and informed written consent obtained. 
Ethical clearance was given for this study. 
Inclusion criteria:- 
 Antenatal women with gestational age < 14 weeks whose fasting blood 
sugar was <92 mg/dl were included. 
Exclusion criteria:- 
• Pregestational diabetes mellitus 
• Gestational diabetes mellitus 
• Renal disease 
• Tuberculosis  
• Bronchial asthma 
• Liver diseases 
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• Cardiovascular diseases 
• Gout  
• Connective tissue disorder  
• Chronic hypertension  
• Drugs causing hyperuricemia ( pyrizinamide . ethambutol, 
levodopa and theophylline) 
Detailed history was obtained from the patient. General examination 
and per vaginal examinations were done. Ultra sonogram was done to 
confirm the gestational age 
 The following details were also collected for the purpose of the study:  
• Age  
• Socioeconomic class  
• Dietary habits  
• Parity  
• Risk factors 
• Height , weight and BMI 
• Fasting blood sugar 
• Base line serum uric acid level 
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Procedure of the study:- 
 Antenatal women less than 14 weeks of gestation included 
Fasting blood sugar value taken 
 
FBS < 92 mg/dl     FBS > 126mg/dl- Overt Diabetes 
Included in the study    FBS 92-125 mg/dl- GDM 
       Excluded from the study 
Measurement of serum uric acid level done 
 
Followed up around 24 to 28 weeks – GDM  
Screening done with OGTT (75 grams of glucose) , IADPSG criteria 
 
Measurement of serum uric acid level:- 
 Venous sample (2ml) was withdrawn from antenatal women who are 
included in the study. The sample was centrifuged to separate the serum and 
stored at -70 degree centigrade till examination. Uric acid measured using 
colorimetric assay with detection limit of 10mg/dl. The coefficient was 0.9%. 
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Screening of gestational diabetes mellitus: 
     All antenatal women were followed up around 24 to 28 weeks and GDM 
screening done with 75 gm glucose (OGTT) as per IADPSG criteria 
IADPSG criteria (2011): 
     OGTT is performed in the morning after overnight fast of at least 8 hours 
     Fasting ≥92mg/dl 
     1hour ≥180mg/dl 
    2hours ≥153mg/dl 
  Diagnosis of GDM is made when any one value is elevated.  
Data was documented in a proforma. The collected data was analyzed 
using Chi-square test, ANOVAtest, student t test for statistical analysis.  
A receiver operator curve analysis was done to decide on a cut off for 
serum uric acid levels which would serve as a marker to predict subsequent 
development of GDM. 
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RESULTS  
 
One hundred and eighty seven pregnant women were enrolled in this 
study. Of these nine were lost follow-up. The mean age of the sample was 23.6 
years (SD=3.3).  The majority was primigravida (64.6%). Base line body mass 
index was calculated using weight and height data. The majority (93.3%) had a 
BMI between 18.5and 24.9, with the mean BMI being 21.9(SD=2.09.) 
 
Table: 1: Maternal age group distribution: 
Age 
Frequency 
N= 178 
Percent 
Less than 20 Years 36 20.2 
21 - 25 Years 95 53.4 
26 - 30 Years 38 21.3 
More than 30 Years 9 5.1 
 
Mean age of the sample was 23.6 years (SD=3.3). 
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Figure 1: Age distribution  
 
 In our study 53.4% were between 21- 25 years, 39.2% were less than 20 
years, 21.3% were between 26 to 30 years and 5.1% were above 30 years 
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Table 2: Serum uric acid levels and development of GDM in different age 
group 
 
Fifteen out of one hundred and seventy eight women developed 
gestational diabetic mellitus on follow up. Table 2 shows that the mean serum 
uric acid level increases with age, and this was found to be statistically 
significant (P value<0.001). The results also showed that a significantly higher 
proportion of older women developed GDM compared to younger women (P 
value<0.05) 
 
 
 
   
Age (in 
years) 
Uric acid 
concentration(mg/dl) OGTT status 
SI 
Range Normal Abnormal(GDM) 
≤20 1.6-4.2 30 6 X
2 
= 
11.409 
21-25 1.7-4.0 93 2 Df = 3 
26-30 1.8-4.2 33 5 P < 0.05 
>30 1.9-4.1 7 2 Significant  
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Parity and serum uric acid levels 
Table 3:  Distribution of serum uric acid level according to parity 
Parity 
Serum uric acid levels at <14 weeks 
1-2 mg/dl 2.1-3mg/dl 3.1-4mg/dl >4mg/dl Total 
Primi 61 30 19 5 115 
Multi 36 15 9 3 63 
  
There was no association between parity and the serum uric acid level at less 
than 14 weeks of pregnancy (P=0.538) 
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Figure 2: Serum uric acid distribution according to parity 
 
61 patients in primigravida and 36 patients in multigravida had serum 
uric acid between 1-2 mg/dl. 30 patients in primigravida and 15 patients in 
multigravida had serum uric acid levels between 2.1-3mg/dl. 19 patients in 
primigravida and 9 patients in multigravida had uric acid level between 3.1-4 
mg/dl. 5 patients in primigravida and 3 patients in multigravida had uric acid 
level more than 4mg/dl. 
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Figure 3: Parity distribution 
 
 Among one hundred and seventy eight women studied most of them were 
primigravida (64.6%). 
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Table 4: Distribution of GDM according to parity 
Parity 
Frequency 
N=178 
Percent GDM 
SI 
x2  = 2.839 
DF = 3 
P = 0.417 
Primi 115 64.6% 9(7.82%) 
Second 47 26.4% 3 
Third 9 5.1% 2 
>third 7 3.9% 1 
 
Primigravidae constituted 64.6% of the total study sample. Out of which 
nine (7.82%) developed GDM. But it was not statistically significant (P=0.417) 
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Figure 4: Development of GDM according to parity 
 
 In our study 9 out of 115 primigravidae developed GDM and 6 out of 57 
multigravidae developed GDM. 
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Figure 5: Gestational age distribution 
 
 
 
In our study 37% of patients were included between 10.1 and 11 weeks of 
gestation, 27.9% were less than 9 weeks of gestation, 25.3% were between 9.1 
and 10 weeks of gestation and 9.7% were between 11.1 and 14 weeks of 
gestation 
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Table 5:- Mean gestational age at which serum uric acid estimation was 
done 
 
GA Number  Percent 
Valid 
percent 
Cumulative 
percent 
Valid 
Below 9 
wk 
50 27.9 27.9 27.9 
9.1-10 wk 45 25.3 25.3 53.2 
10.1- 11 
wk 
66 37 37 90.3 
11.1 14 wk 17 9.7 9.7 100 
Total 178 100 100  
 
 In our study the highest number of serum uric acid estimation were done 
between 10.1 and 11 weeks of gestation 
 There was no significant variation in serum uric acid levels at different 
gestational age in our study. 
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 Figure 6: Gestational age at which serum uric acid estimation done 
 
 
In our study 37% of serum uric acid estimation was done between 10.1 -
11 weeks of gestation. 27.9% were less than 9 weeks 25.3% were between 9.1 
and 10 weeks of gestation and 9.7% were between 10.1 and 14 weeks. 
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BMI and Serum Uric Acid 
Figure 7: Distribution of patients according to BMI 
 
In our study most of the women studied were normal BMI (93.2%) 
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Table 6: Comparison of BMI according to quartile distribution of serum 
uric acid 
BMI 
Serum uric acid at < 14 weeks(mg/dl) 
Total 
P value 
=0.194 
1-2 2-3 3-4 >4 
Normal 30 72 55 9 
166 
(93.3%) 
Obese 2 4 2 1 
12 
(6.7%) 
    
93.3% had normal BMI. Majority of them (127) had serum uric acid 
levels in second and third quartile and 6.7% were obese with their serum uric 
acid levels in second and third quartile. 
There was no significant association between BMI and serum uric acid 
levels in our study. 
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Table 7: Correlation between BMI and development of GDM  
BMI 
OGTT with 75 grams glucose 
Total 
SI 
X2 =1.184 
Df =1 
P = 0.277 
Normal Abnormal 
Normal 151 15 166 
Obese 12 0 12 
No correlation was observed between BMI and development of GDM in 
our study. 
The data was analyzed to explore the association of serum uric acid levels 
with development of GDM (Table 8). The results shows that a significantly 
higher proportion of women with higher serum uric acid levels developed GDM 
compared to those with lower serum uric acid levels( P<0.01) 
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Table 8- Correlation of serum uric acid level with OGTT status 
Serum uric acid concentration 
(mg/dl) 
 
OGTT 
Status  
No.of 
subjects Normal 
Abnormal 
(GDM) 
1.0 - 2.0 32 32 0 
2.1 - 3.0 121 119 2 
3.1 - 4.0 17 12 5  
>4.0 8 0 8 
     
Most of GDM occurs when serum uric acid levels increases 
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Figure 8: 
 
 
In our study 68% of pregnant women had serum uric acid level between 
2.1-3 mg/dl, 18% between 1- 2 mg/dl, 9.5% between 3.1 and 4mg/dl and 4.5% 
had serum uric acid level above 4mg/dl. 
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Figure 9: Relation between GDM and Quartile distribution of serum uric 
acid 
                                                                                                        
In our study 8 patient with serum uric acid level more than 4mg/dl, 5 
patients with serum uric acid between 3.1 and 4mg/dl and 2 patients with serum 
uric acid level between 2.1 and 3mg/dl developed GDM. 
     Finally, a receiver operator curve analysis was done to ascertain a suitable 
serum uric acid cut off so as to suggest as a marker for subsequent development 
of GDM 
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Figure  10: ROC curve for serum uric acid in relation to an out come of 
GDM 
ROC Curve
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Area under the curve –0.914 standard error- 0.051.  
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Table 9 :  Distribution of cases in relation to serum uric acid 
Sr uric acid(mg/dl) Frequency Percent Valid Percent Cumulative Percent 
 
Less than 3.6 153 86.0 86.0 86.0 
More Than 3.6 25 14.0 14.0 100.0 
Total 178 100.0 100.0  
     
In our study 86% of patients had serum uric acid <3.6mg/dl and 14% of 
them had serum uric acid >3.6mg/dl. 
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Figure 11:- 
 
          In our study 86% of them had uric acid level <3.6mg/dl and 14%had uric 
acid level >3.6mg/dl 
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Table 10: – Distribution GDM cases using serum uric acid cut off 3.6mg/dl 
Uric acid(mg/dl) GDM Non GDM Total 
<3.6 2 151 153 
>3.6 13 12 25 
Total 15 163 178 
  
2 patients developed GDM with serum uric acid <3.6 mg/dl and 13 
patients with uric acid >3.6 mg/dl. This shows development of GDM increases 
with increase in uric acid concentration. 
A cut off serum uric acid level of 3.6mg/dl was found to have 92% 
sensitivity; specificity of 99%, for the development of gestational diabetes 
mellitus, as shown in table 10. 
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Figure 12: Relation between serum uric acid and GDM 
 
 
In our study out of 25 patients with serum uric acid level more 
than3.6mg/dl, 13 patients developed GDM and out of 153 patients with serum 
uric acid level less than 3.6mg/dl, 2 developed GDM. 
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Chi square test 
 
 
Value Df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 71.559a 1 .000   
Continuity 
Correctionb 65.141 1 .000   
Likelihood Ratio 46.971 1 .000   
Fisher's Exact Test    .000 .000 
Linear-by-Linear 
Association 71.157 1 .000   
N of Valid Cases 178     
 
 
 
a. 1cells (25.0%) have expected count less than 5. The minimum expected 
count is 2.11. 
b. Computed only for a 2x2 table 
 
         Increased serum uric acid was associated with higher incidence of 
development of GDM, which is statistically highly significant (P<0.01) 
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Risk factors and GDM 
Table 11: Risk factors stratification in the total population studied  
Risk factors No of patients GDM 
Family H/O  DM 8 4 
Previous H/O GDM 6 2 
PCOD 3 0 
BOH 7 1 
Prev H/O Macrosomia 5 1 
 
GDM developed significantly when they had previous H/O GDM and 
family H/O DM 
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Table 12:- Distribution of risk factors with development of GDM 
Uric 
acid(mg/dl) 
Number of 
women 
Risk 
factors 
No risk 
factors 
GDM 
With RF 
Without 
RF 
<3.6 153 19 134 2 0 
>3.6 25 10 15 6 7 
 
Out of 153 women with serum uric acid level <3.6mg/dl, 134 of them had 
no risk factors and 19 of them had risk factors. Among the 25 women with 
serum uric acid >3.6mg/dl, 10 of them had risk factors and 15 of them had no 
risk factors 
       Out of 153 women with serum uric acid level less than 3.6mg/dl, 19 women 
had risk factors of which 2 developed GDM. Out of 25 women with serum uric 
acid level more than 3.6mg/dl, 6 out of 10 women with risk factors and 7 out 
of15 with no risk factors developed GDM.  
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  Table 13: Family history and GDM occurrence 
 
 
 OGTT Total 
Normal Abnormal 
F/H 
Negative 159 11 170 
Positive 4 4 8 
Total 163 15 178 
 
Figure 13: Relation between family history of DM and GDM 
 
 
 
In our study 4 patients had family H/O DM and all were developed GDM 
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Chi-Square Tests 
 Value Df Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 18.761a 1 .000   
Continuity 
Correctionb 13.544 1 .000 
  
Likelihood Ratio 10.314 1 .001   
Fisher's Exact Test    .002 .002 
Linear-by-Linear 
Association 18.655 1 .000 
  
N of Valid Cases 178     
 
a. 1 cells (25.0%) have expected count less than 5. The minimum expected 
count is .67. 
b. Computed only for a 2x2 table 
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Table 14: Previous history of GDM and GDM occurrence 
 
 
 OGTT Total 
Normal abnormal 
Pre GDM 
Negative 159 13 172 
Positive 4 2 6 
Total 163 15 178 
 
 
In our study only two women developed GDM out of 6 women with previous 
history of GDM  
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Figure 14:- Relation between previous H/O GDM and GDM occurrence 
 
 
 
 
In our study 6 women had previous H/O GDM out of which 2 patients 
developed GDM in present pregnancy 
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Chi-Square Tests 
 Value Df Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 4.991a 1 .025   
Continuity 
Correctionb 2.210 1 .137 
  
Likelihood Ratio 3.135 1 .077   
Fisher's Exact Test    .048 .048 
Linear-by-Linear 
Association 4.963 1 .026 
  
N of Valid Cases 178     
 
a. 1cells (25.0%) have expected count less than 5. The minimum expected 
count is .51. 
b. Computed only for a 2x2 table 
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Table 15: PCOD and GDM occurrence 
 
 OGTT Total 
Normal abnormal 
PCOD 
Negative  160 15 175 
Positive 3 0 3 
Total 163 15 178 
 
 
Figure 15: Relation between PCOD and GDM 
 
 
 
In our study 3 had PCOD but none of them developed GDM 
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Chi-Square Tests 
 Value Df Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square .281a 1 .596   
Continuity 
Correctionb .000 1 1.000 
  
Likelihood Ratio .533 1 .465   
Fisher's Exact Test    1.000 .767 
Linear-by-Linear 
Association .279 1 .597 
  
N of Valid Cases 178     
 
a. 2 cells (50.0%) have expected count less than 5. The minimum expected 
count is .25. 
b. Computed only for a 2x2 table 
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Table 16: BOH and GDM occurrence  
 
 
Figure 16:- Relation between BOH and GDM 
 
 
 
In our study 7 women had previous H/O BOH among which one developed 
GDM 
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 OGTT Total 
Normal Abnormal 
BOH 
Negative 157 14 171 
Positive 6 1 7 
Total 163 15 178 
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Chi-Square Tests 
 Value Df Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square .324a 1 .569   
Continuity 
Correctionb .000 1 1.000 
  
Likelihood Ratio .275 1 .600   
Fisher's Exact Test    .466 .466 
Linear-by-Linear 
Association .322 1 .570 
  
N of Valid Cases 178     
 
a. 1cells (25.0%) have expected count less than 5. The minimum expected 
count is .59. 
b. Computed only for a 2x2 table 
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Table 17: Previous history of macrosomia and GDM occurrence 
 
 
 OGTT Total 
Normal abnormal 
Macro 
Negative 159 14 173 
Positive 4 1 ² 
Total 163 15 178 
 
 
Figure 17:-Relation between previous H/O Macrosomia and GDM 
 
 
 
In our study   women had  prev H/O macrosomia out of which one patient 
developed GDM 
0
20
40
60
80
100
120
140
160
Positive Negative
1
14
4
159
GDM
Non GDM
75 
 
 
 
Chi-Square Tests 
 Value Df Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square .893a 1 .345   
Continuity 
Correctionb .016 1 .898 
  
Likelihood Ratio .673 1 .412   
Fisher's Exact Test    .359 .359 
Linear-b y-Linear 
Association .888 1 .346 
  
N of Valid Cases 178     
 
a. 2 cells (50.0%) have expected count less than 5. The minimum expected 
count is .42. 
            In  our study there was a moderately significant correlation between 
the previous history of GDM and OGTT at 24 to 28 weeks with P value of 
<0.048 and a significant correlation between the family history of diabetes and 
OGTT at 24 to 28 weeks of pregnancy( P <0.05) 
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DISCUSSION  
 
            Early intervention and appropriate management in patients with 
gestational diabetes mellitus or at increased risk for developing gestational 
diabetes mellitus will helpful in preventing the adverse maternal and perinatal 
outcome and also protect them from long term consequences. Untreated 
carbohydrate intolerance during pregnancy is associated with higher incidence 
of maternal morbidity and mortality. The purpose of screening, treatment, and 
management of gestational diabetes mellitus is to prevent stillbirth, congenital 
anomalies, recurrent abortion, preeclamsia, intrauterine death and decrease 
incidence of macrosomic babies, thereby reducing maternal and perinatal 
morbidity and mortality. All over the world several studies have shown the 
association of hyperuricaemia in the first trimester with development of 
gestational diabetes mellitus later in life. 
          This prospective  study was conducted in Raja Mirasudhar Hospital 
attached to Thanjavur Medical College, Thanjavur  for a period of one year 
from September 2015.Study was undertaken to find out the association of 
elevated first trimester uric acid   levels with development of GDM. The sample 
size of 187 patients was estimated using power calculation based on the 
prevalence of GDM, and was guided by the statistician. 
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                         In our study, amongst the background variables analyzed, age 
seemed to be significantly associated with an increase in serum uric acid level 
and development of GDM (P<0.05).This finding is consistent with previous 
studies that have reported increasing incidence of GDM and high serum uric 
acid levels with increasing age amongst women. (Carolan et al (2012).,Qui et al 
.,(2013).73 
            Out of 178 women studied, 64.6%were primigravidae and 55.4% were 
multigravidae. In our study, there was no significant difference in serum uric 
acid levels between primigravidae and multigravidae at <14 weeks of pregnancy 
(P=0.538).The same finding has been observed by Dunlop.  W et al., in their 
study on effect of renal handling of uric acid in pregnancy in (1977)74.On the 
contrary Aparna K et al.,(2014)62; has reported significantly higher mean uric 
acid levels in multiparous women. 
            In our study we found no difference in the incidence of development of 
GDM in relation to parity (P=0.417) which was consistent with the results of 
Aparna K., et al.,(2014)62. 
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         In 2012, Nagalakshmi C.et al.,had  stated that development  of GDM is 
increased among primigravida75.While Al  Rowally et al.,(2010); had  shown in 
their study that  multiparous women were at increased risk of developing GDM 
compared to nulliparous women76 .   
            Analyzing the body mass index, 93.3% of pregnant women studied were 
normal BMI (BMI<24.9) and majority of them had their serum uric acid levels 
in second and third quartile.6.7% were obese (BMI>25) with their serum uric 
acid levels also in second quartile and third quartile. Though there was some 
proportional increase in serum uric acid levels with increase in BMI, it was not 
found statistically significant in our study. 
            It was also found in our study  that BMI is not statistically associated 
with development of gestational diabetes mellitus.(P=0.217).This was in 
agreement with the  results of  Laughon .KS et al.,(2008 )55;and Aparna K et 
al.,( 2014)62; who reported that the association between elevated uric acid at 
early trimester and risk of development of GDM was independent of  body mass 
index . 
           In risk factor stratification majority of patients had no family history of 
diabetes though they had higher levels of blood glucose at 24 and 28 weeks of 
pregnancy. There was significant correlation between family history of diabetes 
and one step test with OGTT at second trimester (P<0.05%). 
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This finding of our study was consistent with that of Ratnakaran . R et al., 
(2007)77  .Study conducted by Rasika C, Sunita samal et al.,2014)58  showed that 
established  risk factor for GDM relevant in women with family history of 
diabetes but not be the principal determinant of hyperglycemia in women 
without significant family history. 
            In our study there was a moderately significant correlation (p=0.048) 
between previous history of GDM and OGTT at 24 to 28 weeks of pregnancy. 
Similar finding was also observed in studies done by Sindhuja Anbalagan et al., 
(2012 -2014)61. 
           Other risk factors like bad obstetric history, Poly cystic ovarian disease, 
and previous history of macrosomia were not significantly associated with 
development of GDM. Poly cystic ovarian disease was found to be the main risk 
factor for development of GDM according to Toulis et al.,( 2009); but it was not 
observed in our study. 
      The results from our study suggest that increased serum uric acid in early 
trimester was associated with higher incidence of level of gestational diabetes 
mellitus. This finding is in keeping with the studies of   Laughon et al., (2008)55; 
study and Aparna Kappaganthu et al., (2014)62; which also found a dose related 
increase in risk of development gestational diabetes mellitus with increase in 
serum uric acid levels. They also suggest that elevated serum uric acid could 
serve as a marker for subsequent development of GDM. 
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        To explore this further, we conducted a receiver operator characteristic 
analysis to ascertain appropriate cut- off for serum uric acid level that might 
best predict GDM development. Borger et al., conducted a study and suggested 
that hyperuricemia in first trimester could be used as an effective marker for 
later development of metabolic syndrome and T II diabetes mellitus. 
         However none of our patients were actually hyperuricemic (defined as 
serum uric acid >6 mg/dl)This not withstanding rise in serum uric acid levels 
was still associated with a higher risk of development of GDM.A cut –off of 
3.6mg/dl seemed to achieve a good balance of sensitivity and specificity in our 
study   population. 
         Katherine  et al.,(2008)55;found that serum uric acid levels of more than 
3.6 mg/dl in early gestation is associated with a threefold  increased risk of  
development of gestational diabetes mellitus. 
In 2012,Zhou .j et al59.,  in their study ,measured lipids and uric acid 
concentration in thousand  healthy multigravidae  at twenty weeks of pregnancy 
and showed that hyperuricemic women experienced a 1.99 fold risk for pre 
eclampsia and a 2.34 fold risk for GDM development. Our findings are 
coincides with the association  of  increased  uric acid with increased risk of 
gestational diabetes mellitus  in the non pregnant population (Halkin H et 
al,.1987)51 and also the early pregnancy uric acid concentration in our study 
were similar to those reported by others. 
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         In our study   there was a highly significant correlation between serum 
uric acid  at<14 weeks of gestation  and development of GDM.(Pearson 
correlation).This is due to the fact that serum uric acid levels normally fall  in 
the early trimester and mid trimester and rises to non pregnant values in late 
pregnancy. Elevated or high normal levels of serum uric acid in first trimester 
may be associated with a pre existing metabolic derangements which lead to 
poor maternal physiological adaptations and predisposes the pregnant women to 
development of pregnancy complication like gestational diabetes mellitus. 
          In our study we did not follow up the women after 28 weeks of pregnancy 
and hence feto-maternal outcomes were not analyzed and this was the potential 
limitation of our study. 
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CONCLUSION 
 
The aim of doing a screening test for GDM in the antenatal period is to 
identify the asymptomatic women who will later develop complications of 
pregnancy and to institute effective treatment so that we can be able to reduce 
the morbidity and mortality. Currently, the complications of gestational diabetes 
mellitus in pregnancy are diagnosed only after mid-late gestation.  It is 
important to recognize that the pathology is already established at the time of 
diagnosis of gestational diabetes mellitus in the week of pregnancy. By the time, 
the diagnosis of gestational diabetes mellitus is made the potential perinatal 
outcome may become irreversible.  
 
Hence it becomes mandatory to do the diagnostic/predictive tests to 
diagnose the gestational diabetes mellitus at the earliest. At present estimation 
of serum uric acid is one of the tests available which can predicts the occurrence 
of GDM. Even though the risk factors like obesity, previous history of GDM, 
family history of Type II DM, PCOD, previous history of macrosomia, BOH, 
are associated with the development of GDM, our study showed that pregnant 
women without these risk factors also developed GDM when the serum uric 
acid  level is more than 3.6mg/dl. Serum uric acid estimation is simple to 
perform, affordable to all classes and available in most places.   
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Though our study results suggest that serum uric acid level estimation in 
first trimester can be used as a marker to predict GDM in pregnant women, 
large scale studies are required before it can be recommended as a routine first 
trimester screening test for prediction of gestational diabetes mellitus. So that 
the dreadful complications of GDM can be avoided in future. 
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PROFORMA 
 
NAME: 
AGE: 
OP NUMBER: 
SES: 
PARITY: 
BOOKED/UNBOOKED: 
LMP: 
EDD:  
GESTATIONAL AGE AT RECRUITMENT: 
DATE OF USG: 
OBSTETRIC HISTORY: 
 
PAST MEDICAL/DRUG HISTORY 
 
PERSONAL HISTORY 
 
FAMILY HISTORY: 
 
GENERAL EXAMINATION: 
          Height -                Weight -   - BMI 
          Pulse rate -      Blood pressure - 
CVS EXAMINATION: 
 
RS EXAMINATION: 
 
PER ABDOMINAL EXAMINATION: 
 
BLOOD INVESTIGATIONS: 
           Fasting blood sugar (<15 weeks of GA) 
           Serum uric acid level  
           OGTT with 75g of glucose at 24 to 28 wks 
 
 INFORMATION SHEET 
 We are conducting a prospective study on  SERUM URIC ACID IN EARLY 
PREGNANCY- A MARKER FOR GESTATIONAL  DIABETES MELLITUS  in 
the department of  Obstetrics and Gynaecology, Raja Mirasudar Hospital, Thanjavur – 
613001. 
•   At the time of announcing the results and suggestions, name and identity of 
the patients will be confidential. 
 
• Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
 
• The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid 
in the management or treatment.  
 
 
   
Signature of investigator  Signature of participant 
 
Date: 
 
 CONSENT FORM 
 
 
 
I __________________________________________  hereby give consent to 
participate in the study conducted by DR.NITHYA .D,  post graduate in department of 
OBSTETRICS & GYNAECOLOGY, RAJA MIRASUDAR HOSPITAL , 
THNJAVUR 613001, and to use my personal clinical data and result of investigation 
for the purpose of analysis and to study the nature of disease. I also give consent for 
further investigations 
 
 
Place : 
Date :       Signature of Participant 
 
 
Sr.no Name Age Parity BMI GA F/H
Pre 
GDM PCOD BOH Macro FBS Sr.Uric A GA FBS 1HR 2HR
1 Majlin Begum 29 3 19.5 9W+1D - - - - - 86 2.8 26W+1D 76 156 134
2 Radhika 19 1 18.5 8W+4D - - - - - 88 1.6 24W+6D 82 162 140
3 Sudali 25 1 20 9+4 - - - - - 76 2.6 26+4 78 164 142
4 Suganya 22 2 21.5 10+0 - - - - - 72 3.6 24+6 74 158 136
5 Gokila 28 4 20.5 10+3 - - - + - 68 2.8 27+4 82 170 144
6 Jeyapriya 24 2 21.5 9+3 - - - - - 75 2.6 26+3 84 176 142
7 Yogeshwari 31 3 19.8 9+5 - - - - - 82 2.4 25+2 86 168 140
8 Sandhya 20 1 18.5 7+3 - - - - - 89 3.6 24+5 76 156 132
9 Amirthavalli 19 1 19 10+2 + - - - - 66 2.8 25+4 94 176 154
10 Jamunarani 20 1 20.5 9+4 - - - - - 90 1.2 26+1 88 172 144
11 Gowri 27 2 23 9+2 - - - - - 68 2.8 25+3 84 170 142
12 Maheswari 21 1 24 9+1 - - - - - 78 2.6 24+2 76 154 130
13 Selvakumari 19 1 22.5 8+2 - - - - - 76 2.8 25+3 78 156 144
14 Gowthami 25 2 20.5 9+5 - - - - - 74 2.8 24+1 80 174 146
15 Anjugam 19 1 22.5 9+3 - - - - - 76 2.8 27+1 84 176 150
16 Dhanalakshmi 22 2 23.5 9+0 - - - - - 78 1.6 26+4 80 168 138
17 Asha 28 2 22.5 10+2 - - - - - 72 2.6 25+2 76 174 142
18 Saranya 22 1 20.5 10+0 - - - - - 68 4.2 24+5 88 182 148
19 Shervika 23 2 20 9+5 - - - - - 84 2.4 26+0 84 176 152
20 Revathi 19 1 18.5 7+5 - - + - - 78 3.6 27+1 76 170 138
21 Sumithra 27 2 19 9+3 - - - - - 86 2.8 24+3 82 164 134
22 Malathi 24 1 19.5 10+2 - - - - - 88 3.6 25+1 74 166 140
23 Tamilselvi 20 1 22 12+5 - - - - - 78 2.4 26+2 76 168 142
24 Akila 31 2 24.5 9+2 - - - - - 72 1.3 24+2 58 162 136
25 Hemaladevi 29 3 23.5 10+3 - - - + - 82 2.8 26+5 86 176 148
26 Revathi 24 1 22 8+2 - - - - - 80 2.6 27+3 84 178 138
MASTER CHART
Sr.no Name Age Parity BMI GA F/H
Pre 
GDM PCOD BOH Macro FBS Sr.Uric A GA FBS 1HR 2HR
27 Usha 25 1 19.5 11+0 - - - - - 70 2.8 28+0 82 174 140
28 Iniya 21 1 22 7+3 - - - - - 86 2.6 24+3 74 158 134
29 Vennila 19 1 23 10+5 - - - - - 80 4.2 25+2 90 186 156
30 surya 25 1 24.5 9+4 - - - - - 74 1.4 24+1 86 176 148
31 Vimala 20 1 21.5 7+5 - - - - - 82 2.8 24+6 80 172 142
32 Nathiya 32 3 22 10+3 - - - - - 86 2.8 24+5 68 166 134
33 Rupa 20 2 20.5 9+5 - - - - - 76 2.6 25+2 70 176 142
34 Meena 23 1 23 13+4 - - - - - 68 2.6 26+1 82 172 140
35 Renganayagi 24 1 24.5 10+4 + _ - - - 72 4.2 27+3 86 192 154
36 Arogyaselvi 24 2 22.5 8+4 - - - - - 84 1.6 27+5 80 174 138
37 Suganya 20 1 20 9+2 - - - - - 80 2.8 26+4 84 176 138
38 Chitra 26 1 22.5 10+5 - - - - - 76 2.2 25+6 86 170 142
39 Sudha 21 1 23 9+0 - - - - - 76 2.6 26+1 88 174 150
40 Rameela 20 1 24.5 10+5 - - - - - 74 1.8 24+2 84 168 142
41 Amutha 31 2 21.5 9+5 - + - - - 82 2.6 26+5 78 158 136
42 Deivamani 20 1 22.5 8+2 - - - - - 86 2.8 24+3 76 146 132
43 Selvi 27 1 21 10+4 - - - - - 80 3.6 24+5 94 180 152
44 Kalaiarasi 22 1 19.5 12+5 - - - - - 74 2.6 25+1 86 174 138
45 Arthi 19 1 20 10+3 - - - - - 70 1.2 26+0 88 166 140
46 Rajammal 23 2 21.5 9+4 - - - - - 68 2.6 27+2 80 158 136
47 Karpagam 25 2 20 8+0 - - - - + 64 2.4 27+5 68 170 138
48 Ilavarasi 24 1 21 10+5 - - - - - 72 2.8 26+5 78 172 146
49 Nathiya 21 1 20.5 7+4 - - - - - 78 2.6 24+2 84 178 156
50 Sathyaseela 23 1 19.5 10+1 - - - - - 82 1.6 25+1 82 154 132
51 Akilandeshwari 27 4 18.5 9+3 - - - + - 76 2.4 24+4 76 158 130
52 Arokyamary 19 1 20 9+0 - - - - - 80 2.6 25+4 86 172 142
53 Nithya 23 1 22 10+2 - - - - - 86 2.4 26+1 80 174 140
Sr.no Name Age Parity BMI GA F/H
Pre 
GDM PCOD BOH Macro FBS Sr.Uric A GA FBS 1HR 2HR
54 Sheelarani 24 2 23.5 13+4 - - - - - 84 1.6 24+5 76 168 138
55 Kavitha 20 1 22.5 10+3 + - - - - 82 4.2 26+1 84 178 162
56 Chellamathi 25 4 21.5 8+1 - - - - - 88 2.8 27+5 80 168 150
57 Vennila 28 3 20.5 10+4 - - - - - 72 2.6 28+0 76 164 142
58 Sathya 19 1 23 8+2 - - - - - 76 2.6 24+2 76 172 144
59 Jeevitha 21 1 24.5 11+0 - - - - - 82 1.6 24+5 70 166 138
60 Vidya 25 2 21.5 9+4 - - - - - 84 2.6 25+3 82 176 146
61 Tamilmani 22 1 22.5 8+3 - - - - - 86 2.4 26+0 68 166 138
62 Vasundradevi 25 2 25 10+3 - - - - - 88 2.6 25+5 66 172 142
63 Revathi 32 4 24 12+5 - - - + - 78 2.8 24+6 84 162 130
64 Muthulakshmi 23 1 21.5 10+3 - - - - - 74 2.6 25+5 86 178 148
65 Priya 20 1 22.5 9+5 - - - - - 70 1.2 26+1 80 176 146
66 Nandhini 23 1 23.5 8+4 - - - - - 68 2.6 27+2 78 168 136
67 Subha 28 2 22.5 10+5 - + - - - 64 4.2 26+5 96 180 148
68 Shakilabanu 19 1 21.5 10+3 - - - - - 70 1.8 25+2 76 168 146
69 Gomathi 21 1 22 7+5 - - - - - 72 2.6 24+3 78 174 140
70 Sripriya 22 1 21.5 9+6 - - - - - 76 2.4 26+2 68 170 150
71 Rajathi 19 1 22.5 10+4 + - - - - 82 4.2 27+1 90 188 146
72 Mahilarani 23 2 21.5 10+3 - - - - - 80 2.2 24+1 66 172 136
73 Chinnaponnu 20 1 20 7+1 - - - - - 88 2.4 25+3 76 174 142
74 Paulinmary 31 3 19.5 11+0 - - - - - 76 1.8 26+4 78 176 150
75 Anuvidya 24 2 18 13+4 - - - - - 72 2.6 24=5 84 174 142
76 Krithiga 19 1 19.5 8+2 - - - - - 88 2.8 27+2 86 176 138
77 Prabavathy 21 1 24 8+1 - - - - - 68 2.8 24+5 84 176 140
78 Nanci 23 1 23.5 10+1 - - - - - 76 1.6 25+2 78 164 136
79 Sudha 22 1 22.5 9+3 - - - - - 82 2.8 26+1 82 174 150
80 Nageshwari 20 1 21.5 8+3 - - - - - 84 2.6 26+4 86 170 142
Sr.no Name Age Parity BMI GA F/H
Pre 
GDM PCOD BOH Macro FBS Sr.Uric A GA FBS 1HR 2HR
81 Vijayarani 24 1 24 10+3 - - - - - 86 2.4 24=3 76 166 138
82 Ezhilarasi 26 2 20.5 12+4 - + - - - 78 2.6 24+2 78 168 142
83 Mariyammal 20 1 20 10+3 - - - - - 70 2.2 25+0 84 172 140
84 Rajeshwari 25 2 19.5 11+0 - - - - - 64 2.4 25+6 80 176 138
85 Manjuladevi 27 2 18 8+4 - - - - - 80 1.4 26+1 78 168 134
86 Yazhini 20 1 19.5 8+3 - - - - - 76 3.8 27+0 88 182 152
87 Thenmozhi 21 1 22.5 8=1 - - - - - 68 1.8 27+2 84 170 142
88 Rekha 29 4 20 10+1 - - - + - 58 2.8 26+4 86 172 146
89 Abirami 21 1 21 9+5 - - - - - 62 1.6 25+3 80 174 140
90 Muthulakshmi 20 1 22.5 7+5 - - - - - 66 2.7 26+1 76 158 132
91 Nadhiya 23 1 23 9+2 - - + - - 74 2.6 24+3 84 164 148
92 Suganthii 24 1 24 10+3 - - - - - 82 2.4 24+5 80 168 150
93 Imakulate 31 2 24.5 13+1 - - - - - 70 2.4 25+4 88 176 144
94 Jeenath begam 29 2 22.5 8+4 - - - - - 82 4.2 26+1 90 178 156
95 Gayathri 25 1 21.5 10+3 - - - - - 86 2.4 25+3 86 176 134
96 Sudha 27 2 22.5 8+2 - - - - - 76 2.6 24+2 84 176 150
97 Gowri 23 1 23.5 10+3 - - - - - 82 2.8 25+3 80 178 138
98 Kavitha 21 1 22.5 9+3 - - - - - 84 2.6 24+3 76 164 142
99 Dhavamani 24 1 24 10+2 - - - - - 78 2.8 24+5 84 172 138
100 Selvanayagi 19 1 20.5 9+2 - - - - - 74 1.8 25+1 86 178 146
101 Komaladevi 26 2 18.5 10+4 + - - - - 68 2.6 26+2 80 176 140
102 Angayarkani 23 1 19 8+1 - - - - - 72 1.2 26+4 86 168 136
103 Regapreethi 28 2 18.5 13+2 - - - - + 86 2.8 27+1 78 158 132
104 Anish fathima 24 1 19.5 10+5 - - - - - 78 3.8 28+0 72 164 136
105 Indhumathi 20 1 19 7+2 - - - - - 70 1.4 26+5 78 168 146
106 Punitha 19 1 20 7+1 - - - - - 62 2.6 27+1 84 176 142
107 Gomathi 21 1 22 10+2 - - - - - 60 2.8 26+5 78 166 140
Sr.no Name Age Parity BMI GA F/H
Pre 
GDM PCOD BOH Macro FBS Sr.Uric A GA FBS 1HR 2HR
108 Arogyamary 22 1 24 9+5 - - - - - 78 2.4 24+3 74 168 136
109 Kalaiselvi 20 1 21.5 8+1 - - - - - 82 1.6 25+1 78 172 138
110 Amuthaselvi 23 1 19 10+3 - - - - - 76 2.8 26+4 84 176 138
111 Poongodi 25 2 18.5 10+3 - + - - - 74 2.6 26+1 78 160 132
112 Vanitha 19 1 19.5 13+1 - - - - - 78 3.8 24+5 96 178 152
113 Arogya 21 1 20.5 8+3 - - - - - 62 1.4 26+1 68 152 130
114 Priyadharshini 27 1 19 11+0 - - - - - 68 2.8 25+3 70 160 142
115 Jeenath nilophar 21 1 18.5 9+0 - - - - - 82 2.6 24+3 72 158 132
116 Bharathi 22 1 18 10+3 - - - - - 68 2.8 25+1 76 162 134
117 Pragatha 19 1 19.5 9+3 - - - - - 78 2.4 24+2 80 170 142
118 Kalaiselvi 22 1 18.5 10+4 - - - - - 74 1.8 25+5 84 166 132
119 Thenmozhi 20 1 23.5 8+4 - - - - - 78 2.6 26+3 74 164 138
120 Deepa 24 2 25.5 9+5 - - - - - 82 2.4 27+2 78 160 136
121 Vanathi 27 2 24 10+5 - - - - - 86 3.8 27+5 90 192 152
122 Suganya 27 2 23.5 12+2 - - - - - 84 1.6 24+2 82 156 130
123 Rajamani 25 1 24 10+4 - - - - - 72 2.8 25+1 70 158 132
124 Sridevi 21 1 26 8+1 - - - - - 82 2.6 24+5 68 158 136
125 Prabavathy 27 2 22.5 9+5 + - - - - 86 2.4 25+2 72 156 130
126 Tamil ilakiya 26 2 25.5 7+5 - + - - - 76 3.8 26+2 66 152 130
127 Anushya 20 1 21.5 10+2 - - - - - 78 1.6 26+3 78 166 142
128 Tamilmani 22 1 23.5 8+5 - - - - - 76 2.8 26+1 70 158 134
129 Amuthakani 28 2 24 10+3 - - - - - 82 2.8 24+5 82 166 146
130 Mary britila 28 3 22 9+3 - - - - + 80 4.2 24+3 96 180 146
131 Sujatha 20 1 23.5 8+0 - - - - - 72 2.6 25+2 70 164 138
132 Suganyamani 22 1 21.5 10+4 - - - - - 68 2.8 26+1 76 166 138
133 SRIPRIYA 25 2 22.5 11+5 - - + - - 70 1.4 27+2 78 168 142
134 Akilandeshwari 23 1 24.5 10+5 - - - - - 68 2.8 26+5 84 170 140
Sr.no Name Age Parity BMI GA F/H
Pre 
GDM PCOD BOH Macro FBS Sr.Uric A GA FBS 1HR 2HR
135 Mangayarkarasi 26 1 19.5 8+3 - - - - - 68 2.6 25+1 78 152 136
136 Rani 21 1 22.5 10+3 - - - - - 72 2.4 25+3 80 148 140
137 Mary 27 2 24 9+5 - - - - - 66 2.6 26+1 82 144 132
138 Vijayarani 22 1 25 11+0 - - - - - 58 2.4 25+2 84 156 134
139 Ponnarasi 28 2 23.5 9+6 + - - - - 76 2.6 24+4 78 162 136
140 Suriya 22 1 22.5 8+4 - - - - - 74 1.2 25+0 70 158 140
141 Krithiga 22 1 21.5 10+3 - - - - - 86 2.4 26+2 76 162 136
142 Lavanya 23 1 22 10+5 - - - - - 82 3.6 26+5 80 172 140
143 Malarpriya 22 1 24 8+1 - - - - - 80 2.8 27+2 82 176 142
144 Boomadevi 29 5 23.5 12+4 - - - + - 66 1.8 25+5 78 164 138
145 Ilakiya 22 1 24 7+5 - - - - - 58 2.6 24+3 76 166 142
146 Priya 26 2 21.5 10+5 - - - - - 72 2.8 25+1 78 164 136
147 Maheshwari 23 1 25.5 10+2 - - - - - 84 3.8 25+3 84 172 138
148 Jeyaseeli 26 2 28 1 - - - - - 70 2.4 26+2 82 168 134
149 Udayarani 23 1 22.5 9+2 - - - - - 76 1.2 27+1 80 166 138
150 Vimaladevi 21 1 21.5 10+3 - - - - - 82 2.6 24+4 78 158 130
151 Kamala 25 2 27 13+6 - - - - - 78 1.8 25+5 70 160 142
152 Rajapriya 31 4 23.5 8+5 - - - + - 86 3.8 26+3 86 182 150
153 Tamilpriya 25 1 26 10+5 - - - - - 74 2.8 27+1 82 158 132
154 Umamaheshwari 21 1 21.5 10+1 - - - - - 76 2.6 24+3 76 164 138
155 Malarvizhi 28 2 20.5 8+2 - - - - + 80 2.8 25+1 72 158 130
156 Rathi 23 1 23.5 9+1 - - - - - 82 2.4 26+2 74 164 136
`157 Sowmiya 21 1 22.5 10+5 - - - - - 86 2.6 27+1 80 172 138
158 Buvaneshwari 23 1 24 10+4 - - - - - 76 3.6 24+2 74 168 134
159 Alagi 27 2 25 8+4 - - - - - 68 2.8 24+5 78 170 142
160 Nishanthi 24 1 20.5 13+5 - - - - - 70 3.6 25+0 82 176 138
161 Valli 22 1 19.5 9+2 - - - - - 72 2.6 26+3 80 174 146
Sr.no Name Age Parity BMI GA F/H
Pre 
GDM PCOD BOH Macro FBS Sr.Uric A GA FBS 1HR 2HR
162 Rasiya 23 1 20.5 10+5 - - - - - 76 2.8 25+1 78 176 136
163 Princy 29 1 22 8+0 - - - - - 72 2.4 27+2 72 156 134
164 Komalavalli 33 3 20.5 10+2 - + - - - 68 2.8 24+0 84 194 146
165 Manjuladevi 22 1 21 13+4 - - - - - 76 2.6 25+3 78 158 136
166 Tamilvidya 22 1 23 8+5 - - - - - 58 2.6 26+4 74 162 140
167 Maheshwari 21 1 22.5 9+5 - - - - - 74 2.4 27+1 78 168 136
168 Priyavathani 26 2 24.5 11+0 - - - - - 82 2.8 26+3 82 166 134
169 Suriyakala 28 3 23.5 9+4 - - - - - 70 1.2 25+4 84 168 130
170 Ragini 23 1 22.5 10+3 - - - - - 68 2.2 25+1 78 172 142
171 Thenmozhi 27 2 21.5 7+6 + - - - - 54 3.6 24+2 76 164 136
172 Sudhandradevi 24 1 24 10+4 - - - - - 64 2.6 25+6 80 148 130
173 Nirmala 23 1 21.5 9=1 - - - - - 68 2.8 26+3 76 172 148
174 Amsavalli 22 1 26.5 9+4 - - - - - 78 2.6 25+1 76 168 134
175 Vaideeshwari 28 2 20.5 9+1 - - - - + 62 3.6 26+2 82 176 142
176 Rajalakshmi 23 1 24.5 9+3 - - - - - 80 2.8 27+1 84 170 144
177 Rubadevi 23 1 28.5 12+5 - - - - - 76 2.4 26+3 86 164 136
178 Sathyapriya 25 2 24.5 9+5 - - - - - 66 2.6 25+4 80 166 132
